Ildong Pharmaceutical Group to Pursue Partnering Activities Including 'GLP-1RA Obesity Drug' at BIO USA

Ildong Pharmaceutical Group announced on June 18 that it will participate in '2026 BIO USA' to introduce its new drug pipeline and pursue business activities such as partnering meetings.

Front View of Ildong Pharmaceutical Group Headquarters. Ildong Pharmaceutical Group

'BIO USA' is the world's largest platform for technology and business exchange related to the pharmaceutical and biotechnology industry. This year's event will be held in San Diego, United States, from June 22 to June 25.

During the event, Ildong Pharmaceutical Group plans to explore collaboration opportunities for new drug commercialization—such as research and development, license-out (technology transfer), and open innovation—with numerous international companies, including global partners.

Ildong Pharmaceutical will hold partnering meetings regarding its GLP-1 RA (glucagon-like peptide-1 receptor agonist) 'ID110521156' targeting obesity and diabetes, as well as 'padoprazan,' a P-CAB (potassium-competitive acid blocker) class drug for the treatment of peptic ulcers.

ID110521156 is an orally administered, small molecule-based synthetic new drug candidate that differentiates itself from existing peptide injectables in terms of ▲pharmacological properties ▲manufacturing efficiency and cost-effectiveness ▲user convenience.

Notably, the drug maintains effective blood concentration for over 18 hours and does not accumulate in the body, making it suitable for commercialization as an oral medication with once-daily, long-term dosing due to its ideal pharmacological profile.

Previously, in a Phase 1 clinical trial, ID110521156 demonstrated up to 13.8% weight loss over four weeks and showed a favorable safety profile without serious adverse events such as gastrointestinal disorders or hepatotoxicity, which are representative side effects of existing treatments.

Ildong Pharmaceutical plans to use the Phase 1 clinical data of ID110521156 to engage with international companies, including existing partners, to discuss license-out and other commercialization opportunities.

Padoprazan, the P-CAB compound, is being co-developed with Daewon Pharmaceutical. Daewon Pharmaceutical is currently conducting a Phase 3 clinical trial in Korea to evaluate efficacy and safety for patients with erosive and non-erosive gastroesophageal reflux disease.

Ildong Pharmaceutical is seeking license-out opportunities for padoprazan based on its overseas rights, while also considering subsequent strategies such as launching a new drug under its own brand upon completion of domestic development.

Idience, a subsidiary specializing in anticancer drug development, will present its oncology pipeline, including ▲the PARP inhibitor venadaparib ▲the pan-KRAS inhibitor 'ID12241' ▲and a dual payload ADC (antibody-drug conjugate).

Venadaparib has received orphan drug and fast track designations from the U.S. FDA and is currently undergoing various studies, including a Phase 2a clinical trial for combination therapy in gastric cancer in both Korea and the United States. Last year, a license-out deal worth approximately 70 billion won was signed for the EAEU (Eurasian Economic Union) and GCC (Gulf Cooperation Council) regions.

A representative from Ildong Pharmaceutical Group said, "In addition to the pre-arranged partnering schedules for each subsidiary and pipeline, we plan to carry out networking activities to generate global business opportunities, including discussions on the commercialization of new drug candidates."

This content was produced with the assistance of AI translation services.